Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | PLK4 | O00444 | 4/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906681 | 1.00 | JAK2 (0.52) | JAK2PLK4JAK3IGF1RCSF1R | |
| SCHEMBL30086528 | 0.91 | CSF1R (0.56) | JAK2PLK4JAK3IGF1RCSF1R | |
| SCHEMBL23906834 | 0.91 | CSF1R (0.56) | JAK2PLK4JAK3IGF1RCSF1R | |
| SCHEMBL30086842 | 0.91 | GSK3B (0.47) | JAK2PLK4JAK3AURKAAURKB | |
| SCHEMBL23906211 | 0.91 | GSK3B (0.47) | JAK2PLK4JAK3AURKAAURKB | |
| SCHEMBL25702920 | 0.91 | JAK2 (0.51) | JAK2JAK3IGF1REGFR | |
| SCHEMBL23906923 | 0.90 | JAK2 (0.52) | JAK2PLK4JAK3IGF1RCSF1R | |
| SCHEMBL30086921 | 0.90 | JAK2 (0.52) | JAK2PLK4JAK3IGF1RCSF1R | |
| SCHEMBL23906234 | 0.89 | PLK4 (0.49) | JAK2PLK4JAK3EGFR | |
| SCHEMBL23906549 | 0.89 | PTK2 (0.41) | JAK2PLK4JAK3IGF1RSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885PLK4 1890/4885JAK3 1474/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | JAK2 1187/4885PLK4 1890/4885JAK3 1474/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885PLK4 1890/4885JAK3 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.